Literature DB >> 9390023

The Heidelberg classification of renal cell tumours.

G Kovacs, M Akhtar, B J Beckwith, P Bugert, C S Cooper, B Delahunt, J N Eble, S Fleming, B Ljungberg, L J Medeiros, H Moch, V E Reuter, E Ritz, G Roos, D Schmidt, J R Srigley, S Störkel, E van den Berg, B Zbar.   

Abstract

This paper presents the conclusions of a workshop entitled 'Impact of Molecular Genetics on the Classification of Renal Cell Tumours', which was held in Heidelberg in October 1996. The focus on 'renal cell tumours' excludes any discussion of Wilms' tumour and its variants, or of tumours metastatic to the kidneys. The proposed classification subdivides renal cell tumours into benign and malignant parenchymal neoplasms and, where possible, limits each subcategory to the most commonly documented genetic abnormalities. Benign tumours are subclassified into metanephric adenoma and adenofibroma, papillary renal cell adenoma, and renal oncocytoma. Malignant tumours are subclassified into common or conventional renal cell carcinoma; papillary renal cell carcinoma; chromophobe renal cell carcinoma; collecting duct carcinoma, with medullary carcinoma of the kidney; and renal cell carcinoma, unclassified. This classification is based on current genetic knowledge, correlates with recognizable histological findings, and is applicable to routine diagnostic practice.

Entities:  

Mesh:

Year:  1997        PMID: 9390023     DOI: 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  291 in total

Review 1.  Should there be a size limit for elective nephron-sparing surgery?

Authors:  Kent G Krejci; Bradley C Leibovich
Journal:  Curr Urol Rep       Date:  2003-02       Impact factor: 3.092

2.  Prognostic factors in renal cell carcinoma.

Authors:  Börje Ljungberg
Journal:  Urologe A       Date:  2004-09       Impact factor: 0.639

3.  Multi-colour FISH on preoperative renal tumour biopsies to confirm the diagnosis of uncertain renal masses.

Authors:  Aliaksei Chyhrai; Jimsgene Sanjmyatav; Mieczyslaw Gajda; Olaf Reichelt; Heiko Wunderlich; Thomas Steiner; Enis Tanović; Kerstin Junker
Journal:  World J Urol       Date:  2010-06       Impact factor: 4.226

Review 4.  Mucinous tubular and spindle cell carcinoma of the kidney: the contrast-enhanced ultrasonography and CT features of six cases and review of the literature.

Authors:  Qing Zhang; Wei Wang; Shiwei Zhang; Xiaozhi Zhao; Shun Zhang; Guangxiang Liu; Hongqian Guo
Journal:  Int Urol Nephrol       Date:  2014-08-27       Impact factor: 2.370

5.  [Renal cell carcinoma].

Authors:  A Haferkamp; D Rohde; S C Müller; H Rübben; M Hohenfellner
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

6.  Renal tumor causing haematuria and sepsis.

Authors:  Attila Szendrôi; András Rusz; Eszter Székely; Péter Riesz; Zsolt Kelemen
Journal:  Pathol Oncol Res       Date:  2003-12-22       Impact factor: 3.201

7.  Collecting duct carcinoma: an entity to be redefined?

Authors:  Hélène Kafé; Jean-Marc Verbavatz; Béatrix Cochand-Priollet; Patrice Castagnet; Annick Vieillefond
Journal:  Virchows Arch       Date:  2004-10-08       Impact factor: 4.064

Review 8.  Renal Cell Carcinoma: Molecular Aspects.

Authors:  Aman Kumar; Niti Kumari; Vinny Gupta; Rajendra Prasad
Journal:  Indian J Clin Biochem       Date:  2017-11-13

9.  Chromophobe renal cell carcinoma with microcystic and adenomatous arrangement and pigmentation--a diagnostic pitfall. Morphological, immunohistochemical, ultrastructural and molecular genetic report of 20 cases.

Authors:  O Hes; T Vanecek; D M Perez-Montiel; I Alvarado Cabrero; M Hora; S Suster; J Lamovec; R Curik; V Mandys; M Michal
Journal:  Virchows Arch       Date:  2005-03-09       Impact factor: 4.064

10.  Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome.

Authors:  U Zimmermann; C Woenckhaus; S Pietschmann; H Junker; S Maile; K Schultz; C Protzel; J Giebel
Journal:  Virchows Arch       Date:  2004-08-26       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.